alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › challenges

challenges

9 studies tagged challenges, dated 2010-10-19 to 2025-07-25. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Disclosure of Alzheimer's disease blood-based biomarker results in a primary care setting: Opportunities and challenges 2025-07-25
  2. The potential and challenges of TREM2-targeted therapy in Alzheimer's disease: insights from the INVOKE-2 study 2025-04-25
  3. Cut-points and gray zones: The challenges of integrating Alzheimer's disease plasma biomarkers into clinical practice 2025-03-01

Studies

9 studies carry this tag.

Date range

2010 to 2025

Top journals

  • International journal of geriatric psychiatry 2
  • Alzheimer's & dementia : the journal of the Alzheimer's Association 1
  • Expert review of molecular diagnostics 1
  • Frontiers in aging neuroscience 1
  • Frontiers in pharmacology 1

8 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Disclosure of Alzheimer's disease blood-based biomarker results in a primary care setting: Opportunities and challenges

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. The journal of prevention of Alzheimer's disease 2025-07-25 Biomarkers

    Blood-based biomarkers (BBMs) for Alzheimer's disease (AD) have advanced rapidly and may be a critical tool for broad community-based screening for AD and detection of AD pathology in individuals with cognitive impairment.

  2. The potential and challenges of TREM2-targeted therapy in Alzheimer's disease: insights from the INVOKE-2 study

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Frontiers in aging neuroscience 2025-04-25 TREM2 and immune genetics

    Alzheimer's disease (AD) is a severe neurodegenerative disorder with a growing global burden.

  3. Cut-points and gray zones: The challenges of integrating Alzheimer's disease plasma biomarkers into clinical practice

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2025-03-01 Biomarkers

    Plasma biomarkers for Alzheimer's disease (AD), such as plasma phosphorylated (p)-tau217, offer a more accessible means of testing for the presence of AD pathology compared to cerebrospinal fluid (CSF) or positron emission tomography (PET) methods.

  4. Challenges of using a Fitbit smart wearable among people with dementia

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. International journal of geriatric psychiatry 2023-03-01 Cognitive tests and assessment

    When designing a study using smart wearables such as a Fitbit among people with dementia, consideration should be given to the following: the possible burden on caregivers supporting the use of the device; a lack of familiarity with this technology in the target population; dealing with missing data, and the involvement of the researcher in setting up and supporting use of the device.

  5. Challenge accepted: uncovering the role of rare genetic variants in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Molecular neurodegeneration 2022-01-09 TREM2 and immune genetics

    The search for rare variants in Alzheimer's disease (AD) is usually deemed a high-risk - high-reward situation.

  6. Microglial Drug Targets in AD: Opportunities and Challenges in Drug Discovery and Development

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Frontiers in pharmacology 2019-08-23 TREM2 and immune genetics

    Alzheimer's disease (AD) is a large and increasing unmet medical need with no disease-modifying treatment currently available.

  7. Alzheimer Disease: Scientific Breakthroughs and Translational Challenges

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Mayo Clinic proceedings 2017-06-01 Genetics

    Alzheimer disease (AD) was originally conceived as a rare disease that caused presenile dementia but has come to be understood as the most prevalent cause of dementia at any age worldwide.

  8. Genetic diagnosis and prognosis of Alzheimer's disease: challenges and opportunities

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Expert review of molecular diagnostics 2015-01-29 Genetics

    Alzheimer's disease (AD), the most common form of dementia in western societies, is a pathologically and clinically heterogeneous disease with a strong genetic component.

  9. Alzheimer's disease genetics: current knowledge and future challenges

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. International journal of geriatric psychiatry 2010-10-19 Genetics

    Alzheimer's disease (AD) is highly heritable, but genetically complex.

All topic tags with their study counts